Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.

US Stock Market on March 12: The Dow Jones Industrial Average, the S&P 500 and the Nasdaq Composite indices eked out mild gains amid choppy trade on Wednesday, in some respite for Wall Street bulls ...

China said it will take “resolute measures” to defend its trading rights, but gave no details on how it will respond to U.S.

US traders seek direction after five days of sell-offs as President Donald Trump's tariff announcements continue to hit ...

Facing a global market meltdown, President Donald Trump on Wednesday abruptly backed down on his tariffs on most nations for ...

U.S. President Donald Trump’s tariff announcements and the countermeasures declared by trade partners dominated the week, hitting Wall Street stocks to mark historic declines. The S&P 500 index was ...

This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic tariffs.

Shares of Eli Lilly & Co. LLY shed 6.45% to $738.21 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074.08 and Dow ...

Eli Lilly & Co. closed 18.86% short of its 52-week high of $972.53, which the company reached on August 22nd.

A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. The European Medicines ...

Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1458 ET – Eli Lilly’s LillyDirect expansion is a positive step as access to adequate providers remains a barrier ...